Cytek Biosciences, Inc. (NASDAQ: CTKB) reported Q3 EPS of ($0.05), $0.08 worse than the analyst estimate of $0.03. Revenue for the quarter came in at $48 million versus the consensus estimate of $55.48 million.

For earnings history and earnings-related data on Cytek Biosciences, Inc. (CTKB) click here.